It's been a strong few months for BioSkryb Genomics, and I wanted to share an update from our perspective at Anzu.
The economics of genomics have shifted significantly. In the past two years, the cost of sequencing a single cell's whole genome has fallen by more than 95% from several hundred dollars per cell to somewhere between $12 and $15. That's not a gradual decline. It's a step-change that makes experiments, clinical applications, and large-scale cell atlases feasible today that were not economical 24 months ago. At the same time, the AI community is increasingly looking for high-fidelity biological training data and recognizing that much of the genomic data in existence is too noisy to train reliable models on. Together, these trends create a tailwind for BioSkryb that we believe they’ve been building toward for years.
The science continues to support the thesis. The field is converging on an important idea: our genomes are not static. Every cell in our body accumulates somatic mutations over a lifetime, and the resulting clonal landscapes appear to carry meaningful signal about cancer risk, treatment resistance, neurological disease, and biological aging. A review published in Cellthis spring framed somatic genomics as an emerging engine for drug discovery. That framing, from researchers at the Wellcome Sanger Institute and elsewhere, lines up with what BioSkryb has argued for years. Understanding clonal biology requires single-cell resolution, genome fidelity, and ground truth, not bulk sequencing.
BioSkryb’s presence at AACR in April reflected that momentum. At this year's meeting in Chicago with over 25,000 attendees, BioSkryb's technology was featured in four presentations. The most prominent was a plenary address by Dr. Dan Landau, Director of the New York Genome Center, who highlighted his group's single-cell genomics work to an audience of more than 10,000 scientists and cited BioSkryb’s platform by name. Three additional presentations at the same meeting showcased research enabled by BioSkryb technology across different cancer contexts. We see that kind of visibility, earned through the science itself, as valuable for building credibility in this field.
One paper is worth calling out specifically. A study published this June in Experimental Hematology & Oncology by investigators at Cedars-Sinai Medical Center and Moffitt Cancer Research Center applied BioSkryb’s ResolveOME™ platform to circulating tumor cells from metastatic colorectal cancer patients, profiling genome and transcriptome from the same single cell from a blood draw. The team characterized chromosomal instability architecture, reconstructed tumor phylogenies, and described the immune cell ecosystem alongside the tumor cells, without a tissue biopsy. They also cited BioSkryb’s BaseJumper® analytics platform by name, which the team believes represents the first independent third-party validation of its combined wet chemistry and bioinformatics platform. We see that as a notable commercial milestone.
BioSkryb is also planning a major launch later this year.For the first time we're aware of, researchers will be able to profile DNA, RNA, and the methylome from the same single cell. Methylation is the epigenetic layer that changes with age, disease progression, and environmental exposure. Combined with BioSkryb’s existing whole-genome and transcriptome capabilities, the team believes this will give researchers a more complete view of cellular identity and function than currently available approaches. This carries potential implications for cancer diagnostics, aging biology, and the kind of ground-truth training data that AI models in medicine are likely to require.
BioSkryb Genomics remains a focused, capital-disciplined company and we believe they are well-positioned as the field catches up to where we think the science is heading.
Sincerely,
David Michael, Managing Partner, Anzu Partners
PORTFOLIO COMPANY UPDATES
ExOne Launched the S-Print Pro™ to Make Industrial Sand 3D Printing More Affordable for Foundries Worldwide
ExOne, the global leader in binder jet 3D printing of sand and ceramics, launched the S-Print Pro™, a compact industrial sand 3D printer that brings production-grade binder jetting to small and mid-sized foundries, pattern makers, and print service providers.
The S-Print Pro is designed for smaller foundries and pattern shops that compete primarily on cost and flexibility. Their work focuses on low-volume casting and contract manufacturing, spare-part production, custom components, and niche alloys or regional supply chains — often with limited automation and digitization.
Nirrin Launched TALOS™, a Protein Quantitation System Designed for Modern Biopharmaceutical Manufacturing Workflows and Announced Distribution Partnership in Japan
Nirrin Technologies, a developer of analytical tools designed to transform bioprocess workflows, announced the commercial launch of TALOS™,a direct protein quantitation system built on the company’s proprietary High-Precision Tunable Laser Spectroscopy (HPTLS™) technology. TALOS™ simplifies protein quantitation across biopharmaceutical workflows by replacing traditional variable pathlength UV workflows with fixed-path near-infrared (NIR) measurement of the peptide backbone.
TALOS™ is available for order now in the United States, with availability expanding across North America, Europe and Japan. To request a demonstration or technical consultation, visit https://www.nirrin.tech/talos or contact info@nirrin.tech.
Nirrin also announced the appointment of S.T. Japan as its exclusive distribution partner for the TALOS™ protein quantitation system in Japan.
S.T. Japan, a specialized provider of spectroscopic analysis technologies, analytical systems, and scientific instrumentation, will serve as the exclusive commercial representative for TALOS™ throughout Japan, providing local sales, technical support, and application expertise to customers in the biopharmaceutical, life sciences, and academic sectors. As part of the agreement, S.T. Japan will purchase a TALOS™ demonstration system, establishing local evaluation capabilities that will allow prospective customers throughout Japan to assess the technology using their own samples and workflows.
Niron Magnetics Applauded Historic Congressional Legislation Recognizing Rare-Earth-Free Permanent Magnets and Appeared in Wall Street Journal
Niron Magnetics,the leader in rare-earth-free Iron Nitride permanent magnets, applauded the introduction of landmark congressional legislation that would establish a federal framework to incentivize the domestic production and use of permanent magnets across America’s defense, energy, and manufacturing sectors.
The Magnets Value Chain Support Act of 2026, creates a federal framework that, for the first time, incentivizes both sides of the permanent magnet supply chain: the domestic producers making permanent magnets, and the OEMs incorporating them into their products.
For Niron Magnetics, the bill’s technology-neutral framework represents a fundamental shift in federal policy, one that recognizes Iron Nitride on equal footing with rare earth magnets in U.S. industrial policy.
InterVenn Biosciences and Aranscia Expand Commercialization Partnership for GlycoKnow™ Ovarian Cancer Diagnostic Test
InterVenn Biosciences, a life sciences company unlocking the value of glycoproteomics for the development of transformational healthcare solutions, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology solutions, announced an expansion of their commercialization partnership to broaden access to InterVenn’s flagship GlycoKnow™ Ovarian cancer diagnostic test for clinicians and researchers.
Aranscia and InterVenn previously announced a multi-year partnership providing InterVenn with access to Aranscia’s platform of clinical workflow software solutions, including Spesana and 2bPrecise, to drive commercialization of GlycoKnow Ovarian. The expanded scope broadens access to InterVenn’s diagnostic solutions across Aranscia’s expansive network of health systems, multi-site women’s health and oncology groups, and individual physicians. Additional Aranscia platform solutions will also help to improve the fidelity and efficiency of supporting insights for InterVenn’s research studies in concert with a growing base of clinical partners, including the delivery of longitudinal insights at the point of care.
ImmunoScape was included in a Deal Street Asia* Deep Tech review report.
Xendee was featured in a Data Center World article on how complex microgrids support data center power strategies.
MedCrypt was included in Becker’s Health IT’s list of healthcare cybersecurity companies to know.
*Requires subscription to read
Join Our Ecosystem
Anzu Partners and our portfolio companies are growing, and we’re always looking for exceptional talent. Whether you're seeking new career opportunities or exploring ways to collaborate, we invite you to connect with us and become part of our network.
To stay up to date on the latest news from both Anzu and our portfolio companies, follow us on social media.
ABOUT ANZU PARTNERS
Anzu Partners is an investment firm that focuses on industrial and life science technology companies with the potential to transform their industries. Anzu works with entrepreneurs to develop and commercialize technological innovations by providing capital alongside deep experience in business development, market positioning, intellectual property, global connectivity, and operations. For more information, please visit https://anzupartners. com/.
The information contained in this newsletter is being provided by Anzu Partners for informational purposes only. The information was obtained from various sources, but Anzu Partners cannot assure its accuracy. This is neither an offer to sell nor a solicitation for an offer to buy an interest in any fund managed by Anzu Partners. Any such offer or solicitation will only be made to qualified potential investors pursuant to a private placement memorandum. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.
You are receiving this email because you requested to be added to Anzu Partners' monthly newsletter distribution list.
